Skip to main navigation

About
R&D
Pipeline
Investors & Media
Careers

Investors & Media

Overview
News
Events & Presentations
Annual Reports
Stock Information
- Stock Quote & Chart
- Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
- FAQs
- Investor Contact

News

Year

March 4, 2021

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results

March 2, 2021

NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer

February 25, 2021

NGM Bio to Present at the Cowen 41st Annual Health Care Conference

February 9, 2021

NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

January 12, 2021

NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology

January 5, 2021

NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock

January 4, 2021

NGM Bio Announces Proposed Offering of Common Stock

Stock Quote

Contact Information

Investor Relations:
ir@ngmbio.com

Media Relations:
media@ngmbio.com

Toolkit

© 2021 NGM Biopharmaceuticals.

All Rights Reserved.

Privacy Policy.

Top